Clinical trials: Multiple Dose
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Healthy
A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255
1. To evaluate the safety and tolerability of LC51-0255 in healthy male subjects 2. To evaluate the pharmacokinetic/pharmacodynamics characteristics (PK/PD) of LC51-0255 in healthy male subjects 3.
- Trial name
- NCT03174613
- Testing
- LC51-0255
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- LG Chem
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Healthy
AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers
The aims of the study are to evaluate the safety, tolerability and pharmacokinetics of AZD8075 in healthy male subjects at increasing doses when given for 14 days
- Trial name
- NCT00829127
- Testing
- AZD8075
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers - Liver Diseases
A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.
In this trial, medicine NNC0560-0004 given in capsule form will be compared to placebo in healthy volunteers. Participants will either get NNC0560-0004 or placebo. Which treatment they get is decided by chance.
- Trial name
- NCT06133270
- Testing
- NNC0560-0004
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteer
A Study of MCAF5352A in Healthy Volunteers
This single-center, randomized, placebo-controlled, double-blind, multiple ascending dose study will evaluate the safety, pharmacokinetics and immunogenicity of MCAF5352A in healthy volunteers.
- Trial name
- NCT01540760
- Testing
- MCAF5352A
- Where
- Canada
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin
This is a phase I trial to evaluate tacrolimus blood levels after topical application of tacrolimus twice daily on healthy skin.
- Trial name
- NCT03673527
- Testing
- topical formulation of tacrolimus
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Autoimmune Hepatitis
A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule
The purpose of this study is to compare the pharmacokinetics of JKB-122 tablets with JKB-122 capsules in healthy male subjects subjects.
- Trial name
- NCT04313205
- Testing
- JKB-122 in capsule or tablet form
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Healthy Subjects
Study of Orally Administered BEBT-503 in Healthy Subjects
This is a Phase I, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetic of orally administered BEBT-503 will be assessed in healthy adult subjects.
- Trial name
- NCT05391880
- Testing
- BEBT-503 20mg, BEBT-503 40mg, BEBT-503 80mg
- Where
- Australia
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- BeBetter Med Inc
Healthy
Dose Study of ANX1502 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ANX1502 (prodrug) and ANX1439 (active drug) in healthy participants.
- Trial name
- NCT05521269
- Testing
- ANX1502
- Where
- Netherlands
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Annexon, Inc.
Dyspepsia
Pharmacokinetic Study of Levosulpiride
The aim of this study was to characterise the pharmacokinetic properties and assess the safety of different formulations of levosulpiride in healthy Chinese volunteers.
- Trial name
- NCT02481583
- Testing
- Levosulpiride
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Healthy
Interaction Between ABT-335, Rosuvastatin and Warfarin
This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.
- Trial name
- NCT00487136
- Testing
- Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers
This is a phase I, randomised, double-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HSK31858 in healthy…
- Trial name
- NCT05663593
- Testing
- HSK31858, tablet
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Healthy
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of multiple intravenous…
- Trial name
- NCT01664221
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Healthy
First-in-Human Single and Multiple Dose of GLPG2222
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of GLPG2222 given to healthy subjects, compared to placebo (Part 1).
- Trial name
- NCT02662452
- Testing
- GLPG2222 single dose, GLPG2222 multiple doses
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Obese, Healthy
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
- Trial name
- NCT05835752
- Testing
- RAY1225
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Healthy
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants
The purpose of this study is to assess the effects of pioglitazone, once daily (QD), on brain hemodynamics in healthy elderly participants.
- Trial name
- NCT01456117
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Takeda
COVID-19
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
The purpose of this study is to assess the immunogenicity and safety of SCB-2023 trivalent vaccine compared to the prototype SCB-2019 monovalent vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19…
- Trial name
- NCT05926440
- Testing
- SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
- Where
- 3 sites in Philippines
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Healthy
A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.
- Trial name
- NCT06716190
- Testing
- Mid-dose bid BI 3731579, Midazolam, Low-dose bid BI 3731579
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.